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Abstract
Though long-term administration of proton pump inhibitor (PPI) imposed the risk of gastrointestinal track tumori-
genesis by accompanied hypergastrinemia, no overt increases of colon cancer risk were witnessed after a long-term
cohort study. Our recent investigation revealed that PPI prevented colitis-associated carcinogenesis through anti-
inflammatory, anti-oxidative, and anti-mutagenic mechanisms in spite of hypergastrinemia. Therefore, we hypothe-
sized that PPI might either antagonize the trophic action of gastrin on gastrointestinal tumorigenesis or synergize
to exert augmented anti-tumorigenic actions.We challenged APCMin/+mice with gastrin, PPI, PPI and gastrin together
for 10 weeks and counted intestinal polyposis accompanied with molecular changes. Gastrin significantly increased
intestinal polyposis, but combination of PPI and gastrin markedly attenuated intestinal polyposis compared to gastrin-
promoted APCMin/+ mice (P< .001), in which significant β-catenin phosphorylation and inhibition of β-catenin nuclear
translocation were observed with PPI alone or combination of PPI and gastrin, whereas gastrin treatment significantly
increased β-catenin nuclear translocation. Significant footprints of apoptosis, G0/G1 accumulation, inactivation of p38
and extracellular signal–regulated kinase, decreased expressions of CD31, and inhibition of tumor necrosis factor–α
and cyclooxygenase-2 were noted in the combination group. In vitro investigations were similar to in vivo findings as
shown that PPI treatment inhibited the binding of gastrin to its receptor, inactivated β-catenin–associated signaling
including Tcf/Lef and glycogen synthase kinase β, and paradoxically inhibited β-catenin–associated proliferative activ-
ities. Our investigations explain why colon cancer risk has not increased despite long-term use of PPIs and provide
a rationale for using PPI to achieve anti-tumorigenesis beyond acid suppression.
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Introduction
Gastrin, which is produced by G cells in the gastric antrum, is fun-
damentally responsible for the stimulation of acid secretion from pa-
rietal cells but also acts as a potent cell growth factor, leading to
either the maintenance of the gastric mucosa and proliferation of
enterochromaffin-like cells or notably neoplastic transformation [1].
Gastrin is known to bind to the cholecystokinin B receptor (CCKBR),
which mediates proliferative action through signal transduction path-
ways. Because not only colorectal cancer cells but also nontransformed
colon epithelium cells express the CCKBR [2], gastrin and their recep-
tors are regarded as potential risk for gastrointestinal cancer.
Abbreviations: COX, cyclooxygenase; HIF, hypoxia-inducible factor; IL, interleukin;
PPI, proton pump inhibitor; TNF, tumor necrosis factor; VEGF, vascular endothelial
growth factor
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The development of a proton pump inhibitor (PPI) and its wide-
spread prescription for blocking acid secretion lead to hypergastrinemia,
which can increase the risk of colorectal cancer, particularly in patients
with Zollinger-Ellison syndrome, pernicious anemia, and Helicobacter
pylori infection [3]. However, a recent clinical study of a large-scale
cohort and prospective investigation reported that hypergastrinemia
following long-term PPI therapy at a regular dose is not associated with
an increased risk of colorectal cancer [4]. This is quite in contrast to
results from animal models of colon carcinogenesis, in which hyper-
gastrinemia clearly increased the incidence and growth rate of an epithe-
lial neoplasm [5]. As a plausible explanation of the unexpected no risk
of colon cancer in spite of hypergastrinemia, two speculations were pos-
sible. One is the double-edged sword role of gastrin in tumorigenesis;
gastrin suppresses the growth of CCKBR expressing colon cancer cell
by inducing apoptosis in vitro and in vivo [6], whereas it has trophic
effects on colon carcinogenesis [5]. The other is preventing action of
PPI on hypergastrinemia-associated tumorigenesis. Therefore, the exact
role of gastrin in the control of cancer cell growth remains controversial
and requires further investigation.
PPIs are potent blockers of gastric acid secretion and are widely pre-
scribed for treatment of acid peptic disorders [7]. However, PPIs have
been found to have additional anti-oxidant properties and direct effects
on neutrophils, monocytes, endothelial cells, and epithelial cells that
might prevent inflammation beyond authentic gastric acid–suppressive
action through blocking efflux of hydronium in parietal cells. In detail,
PPIs may mediate anti-inflammatory effects through the inhibition
of angiogenic growth factors and the expression of the intercellular
adhesion molecule–1 and the vascular cell adhesion molecule–1, as
well as the endothelial-dependent neutrophil adhesion [8], and induce
selective induction of apoptosis in cancer cells.
Our recent investigation shows that long-term PPI treatment
inhibited colitis-associated carcinogenesis, supported with selective
cancer cell apoptosis, anti-oxidative action, and anti-inflammatory
actions as well as regulation of angiogenic factors including vascular
endothelial growth factors (VEGFs) [9]. However, the question arose
as to how hypergastrinemia consequent to long-term PPI contributed
to colon anti-tumorigenesis. On the basis of this publication, we
hypothesized that PPI might impose the antagonistic role of hyper-
gastrinemia or exert anti-tumorigenesis through the paradoxically
reciprocal augmented action of anti-tumorigenesis with gastrin. The
combination of PPI and gastrin contributed to the attenuation of
intestinal polyposis either through inhibition of β-catenin–associated
proliferation or gastrin-associated inflammation in vitro and in vivo
APCMin/+ mice model.
Materials and Methods
Materials and Cell Culture
Pantoprazole among PPIs including omeprazole, lansoprazole, and
rabeprazole, was chosen after a preliminary study that pantoprazole
was the most stable in inhibiting proton pump activities and was
purchased from Amore-Pacific Pharma (Seoul, Korea). Gastrin was
purchased from Sigma-Aldrich (St Louis, MO). The HCT116 human
colorectal cancer cell line was obtained from American Type Culture
Collection (ATCC, Manassas, VA) several years ago. The HCT116 cell
line has been tested and authenticated with short tandem repeat profil-
ing method in Korean Cell Line Bank in January 2013. The infor-
mation on the HCT116 cell line was provided in the Supplemental
data. The HCT116 human colorectal cancer cell line was cultured in
McCoy’s 5A medium containing 10% (vol/vol) FBS and 100 U/ml
penicillin. Cells were maintained at 37°C in a humidified atmosphere
containing 5% CO2.
Antibodies
β-Actin, α-tubulin, β-catenin, phospho–extracellular signal–regulated
kinase (ERK), ERK, survivin, CCKBR, and cyclooxygenase-2 (COX-2)
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Cyclin D1, cyclin E, cyclin A, cyclin-dependent kinase (CDK)
2, CDK4, phospho-p38, p38, phospho–c-Jun N-terminal kinase
( JNK), JNK, phospho–β-catenin, Bcl-2, cleaved caspase-3, cleaved
caspase-8, poly(ADP-ribose) polymerase (PARP), and phospho–
glycogen synthase kinase 3β (GSK3β) antibodies were purchased from
Cell Signaling Technology (Denver, MA).
Cell Proliferation Assay
In a cell proliferation assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma-Aldrich), cells were seeded
into 96-well plates at 1 × 104 to 2 × 104 cells per well overnight before
drugs were added. The cells were incubated with different concen-
trations of gastrin for 12 hours. Cells were incubated with MTT for
2 hours and read at an OD of 570 nm.
Cell Cycle Analysis and Apoptosis Analysis
Cells were treated with gastrin, a PPI, the combination of gastrin
and a PPI, or phosphate-buffered saline (PBS) as a control. After
trypsinization, cells were fixed in 70% ethanol for 30 minutes at
4°C. The cells were washed twice with PBS and incubated for
30 minutes in the dark at 37°C in 1 ml of PBS containing 100 μg of
propidium iodide and 100 μg of RNase A. Flow cytometric analysis was
completed, and the proportion of cells was assessed by the histograms
generated using the computer program Mod-Fit. Apoptosis was
analyzed by FACS using the Annexin V–FITC Apoptosis Detection
Kit (BD Biosciences, Bergen, NJ).
Reverse Transcription–Polymerase Chain Reaction and
Real-Time Polymerase Chain Reaction
After treatment, the medium was removed by suction, and cells were
washed with Dulbecco’s PBS twice. RiboEX (500 μl; GeneAll, Seoul,
Korea) was added to plates that were incubated for 10 minutes at 4°C.
RiboEX was harvested and placed in a 1.5-ml tube, and 100 μl of
chloroform was added and gently mixed. After incubation for 10 min-
utes in ice, samples were centrifuged at 10,000g for 30 minutes.
Supernatants were extracted and mixed with 200 μl of isopropanol,
and mixtures were incubated at 4°C for 1 hour. After centrifuging
at 13,000g for 30 minutes, the pellet was washed with 70% (vol/vol)
ethanol. After allowing the ethanol to evaporate completely, the pellet
was dissolved in 100 μl of diethylene pyrocarbonate–treated water
(Invitrogen Life Technologies, Carlsbad, CA). cDNA was prepared
using a reverse transcriptase originating fromMurine-Moloney leukemia
virus (Promega, Madison, WI), according to the manufacturer’s instruc-
tions. The polymerase chain reaction (PCR) primers used are shown
in Table 1. PCR was performed using over 30 cycles of 94°C for
20 seconds, 58°C for 30 seconds, and 72°C for 45 seconds. Oligo-
nucleotide primers were purchased from Bioneer (Seoul, Korea).
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ELISA and Sandwich ELISA
Small intestine tissues were homogenized with 1 ml of cell lysis
buffer (Cell Signaling Technology) containing 1 mM PMSF, incubated
for 20 minutes, and centrifuged at 10,000g for 10 minutes. Super-
natants were recentrifuged and collected. All samples were stored at
−80°C until required. Mouse tumor necrosis factor–α (TNF-α) and
mouse prostaglandin E2 (PGE2; R&D Systems, Minneapolis, MN)
ELISAs were performed according to the manufacturer’s instructions.
The sandwich ELISA measures the amount of antigen between
two layers of antibodies (a capture and a detection antibody). A
96-well polyvinyl chloride plate containing the capture antibody,
anti–cholecystokinin 2 receptor (Santa Cruz Biotechnology), at a
concentration of 10 μg/ml in carbonate/bicarbonate buffer (pH
7.4) was covered with an adhesive plastic and incubated overnight
at 4°C. The coating solution was removed, and the plate was washed.
The remaining protein-binding sites were blocked in the coated wells
by incubation with 5% BSA buffer overnight at 4°C. Cells were
treated with gastrin, a PPI, or the combination of PPI and gastrin,
or PBS as a control. Samples were added to each well and incubated
for 90 minutes at 37°C. The samples were removed, the plates were
washed, and the detection antibody, anti-gastrin (biotin; ABcam,
Cambridge, MA), was added to each well and incubated for 2 hours
at room temperature. The plate was washed, and the secondary
antibody, HRP-conjugated streptavidin, was added. The plate was
incubated for 2 hours at room temperature and washed. A 3,3′,5,5′-
Tetramethylbenzidine solution was added to each well, the plate was
incubated for 15 to 30 minutes, an equal volume of stopping solu-
tion (2 M H2SO4) was added to the plate, and the plate was read at
an OD of 450 nm.
Luciferase Reporter Activity Assay
Cultured cells were seeded at a concentration achieving 80% conflu-
ence in 12-well plates for 24 hours before transfection. The cells were
transiently transfected with 0.2 μg/well of a translucent Tcf/Lef-Luc
reporter vector, which was designed to measure the transcriptional
activity of Tcf/Lef-responsive genes. After transfection, the cells were
treated with specific reagents such as gastrin, PPI, or the combination
of PPI and gastrin in serum-free medium at the indicated time pe-
riods. The cell lysates were then obtained with 1× reporter lysis buffer
(Promega). The luciferase activity was assayed using a Victor2 lumino-
meter (PerkinElmer, Waltham, MA). The relative luciferase activity
was calculated after normalization of cellular proteins. All values are
expressed as the percentage of activity relative to basal activity.
Immunohistochemical Staining
After paraffin blocks were dewaxed and rehydrated with graded alco-
hol, tissue sections were heated in pressure jars filled with 10 mM/l -
citrate buffer in a microwave for 10 minutes. Slides were cooled in
water for 15 minutes and washed in PBS. The slides were incubated
overnight with the primary antibody. After incubation, a subsequent
reaction was formed using a VECTOR kit (Vector Laboratories,
Inc, Burlingame, CA). Finally, the slides were incubated with
3,3′-diaminobenzidine (Invitrogen Life Technologies) and counter-
stained with hematoxylin (Sigma-Aldrich).
Terminal Deoxynucleotidyl Transferase–Mediated dUTP
Nick End Labeling Staining
Apoptosis was visualized using a terminal deoxynucleotidyl trans-
ferase (TdT) fRAGel DNA Fragmentation Detection Kit (Oncogene
Research Products, La Jolla, CA). After routine deparaffinization,
rehydration, and washing in PBS (pH 7.4), tissues were digested with
proteinase K (20 μg/ml in PBS) for 20 minutes at room temperature
and washed. Tissues were incubated in equilibration buffer for 10 min-
utes and treated with TdT enzyme at 37°C for 1 hour. To determine
the apoptotic index in each group, TdT-mediated dUTP nick end
labeling (TUNEL)–immunostained sections were scanned under
low-power magnification (×100) to locate the apoptotic hotspots.
Animals and Study Protocol
C57BL/6J-APCMin/+ mice on a pure C57BL/6 background were
obtained from Jackson Laboratories (Bar Harbor, ME). APCMin/+
mice were verified as previously described by PCR using tail DNA
extracted. The sequences of PCR primers were recommended by
Jackson Laboratories. Five-week-old male C57BL/6J-APCMin/+ mice
were fed sterilized commercial pellet diets (Biogenomics, Seongnam,
South Korea) and sterile water ad libitum and housed in an air-
conditioned biohazard room at a temperature of 24°C. One group
of eight mice (group 1) was given intraperitoneal (i.p.) injections of
PBS (iNtRON Biotechnology, Seongnam, South Korea) three times
per week for 10 weeks. The second group (group 2) was given
i.p. injections of gastrin (10 μg/kg; Sigma-Aldrich) three times per week
for 10 weeks. The third group (group 3) was given i.p. injections of
PPI (pantoprazole, 8.0 mg/kg; Amore-Pacific Pharma) three times
per week for 10 weeks. The fourth group (group 4) was given
i.p. injections of gastrin and PPI three times per week for 10 weeks
(Figure 1A). Among PPIs, including omeprazole, lansoprazole,
rabeprazole, and pantoprazole, we choose pantoprazole because in the
preliminary study, the highest stability of proton pump inhibiting
action in an aqueous condition was seen in pantoprazole. Animals
were handled in an accredited animal facility in accordance with inter-
national policies of the Association for Assessment and Accreditation of
Laboratory Animal Care. Following killing, the small intestine was
resected, opened longitudinally, and washed with sterile PBS. The
small intestine was divided by length into three equal sections (proximal,
middle, and distal segments). Polyps on the intestinal segments were
counted, and their sizes were measured with a caliper.
Statistical Analysis
All the experiments in this study except in vivo animal experiment
were repeated more than thrice, and the results are expressed as the




Forward, 5′-AGG TCG GAG TCA ACG GAT TTG G-3′
Reverse, 5′-AA GTC TTC TGG GTG GCA GTG ATG-3′
IL-8 Forward, 5′-TGG GTG CAG AGG GTT GTG-3′
Reverse, 5′-CAG ACT AGG GTT GCC AGA TTT A-3′
HIF-1α Forward, 5′-ACA GCA GCC AGA CGA TCA TGT-3′
Reverse, 5′-AAA TGA GCT GTC TGT GAT CCA GCA TT-3′
VEGF Forward, 5′-TCG GGC CTC CGA AAC CAT G-3′
Reverse, 5′-GGT TCC CGA AAC CCT GAG G-3′
PDGF Forward, 5′-AGG AAG CCA TTC CCG CAG TT-3′
Reverse, 5′-CTA ACC TCA CCT GGA CCT CT-3′
COX-2 Forward, 5′-GGT CTG GTG CCT GGT CTG ATG ATG-3′
Reverse, 5′-GTC CTT TCA AGG AGA ATG GTG C-3′
Mouse TNF-α Forward, 5′-CTG AGG TCA ATC TGC CCA AGT AC-3′
Reverse, 5′-CTT CAC AGA GCA ATG ACT CCA AAG-3′
Mouse β-actin Forward, 5′-GGT GGG AAT GGG TCA GAA GG-3′
Reverse, 5′-TCA CGC ACG ATT TCC CTC TC-3′
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means ± SD. The data were analyzed by one-way analysis of variance,
and the statistical significance between groups was determined
by Duncan multiple range test. Statistical significance was accepted
at P < .05.
Results
PPI Ameliorated Gastrin-Promoted Intestinal Polyposis in
APCMin/+ Mice
APCMin/+ mice are known to develop multiple intestinal polyposis
based on the accumulation of β-catenin owing to an apc gene mutation
[10]. As shown in Figure 1, 15-week-old APCMin/+ mice developed mul-
tiple intestinal polyps, mostly on the small intestine. However, 10 μg/kg
gastrin significantly accentuated intestinal polyposis (P < .005), con-
firming the trophic effect of gastrin on intestinal polyposis. A PPI alone
(pantoprazole, 8 mg/kg) in the current study attenuated intestinal poly-
posis compared to the control and more significantly through the
combination of PPI and gastrin (P < .001; Figure 1 and Table 2),
signifying the augmented inhibitory action of intestinal polyposis with
co-administration of PPI and gastrin. These results suggest that besides
the direct anti-tumorigenic action of PPI, PPI might synergize with
gastrin in inhibiting intestinal polyposis.
Combination of PPI and Gastrin Prevented β-Catenin
Activation and Induced Apoptosis as Augmented
Anti-Polyposis Mechanisms
To document how PPI blocked the gastrin-promoted trophic
effect in intestinal polyposis, we hypothesized that the anti-polyposis
effect of PPI alone or combination of PPI and gastrin might be due
to increased phosphorylation of β-catenin and subsequently de-
creased nuclear translocation of β-catenin. As shown in Figure 2A,
gastrin significantly decreased the phosphorylation of β-catenin in
the whole lysates from intestinal mucosa of APCMin/+ mice (P < .05)
in group 2, whereas phospho–β-catenin was increased in group 3
and preserved in group 4. Further confirmations of these β-catenin
changes were done by immunohistochemistry staining (Figure 2B).
As seen in groups 1 and 2, β-catenin was increasingly expressed in
the colonocyte nucleus in APCMin/+ mice, whereas groups 3 and
4 showed staining of β-catenin in the cytoplasm and membrane of
the colonocyte (P < .05; Figure 2B). Next, we have checked the
Figure 1. The gross morphology of intestinal polyposis according to group in an APCMin/+ mouse model. (A) The schematic overview of
the experimental protocol of an animal model for small intestine polyposis using APCMin/+ mice. (B) Gross and microscopic pathologies
according to group: control, gastrin, PPI alone, and the combination of PPI and gastrin. Representative gross and pathologic pictures
(original magnification, ×1). (C) The polyps in the small intestine of the individual mouse were counted according to group. Gastrin
administration significantly increased the polyp number, but PPI treatment markedly decreased in groups 3 and 4. (D) Total polyps in
the whole small intestine were counted according to group. Gastrin administration significantly increased polyp number (P < .005), but
statistically significant decreases in polyp numbers were observed in groups 3 and 4 compared with group 2 (P < .001). Results are
expressed as means ± SD (n = 8).
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Figure 2. The changes in β-catenin, cell cycle, and apoptosis according to animal group. (A) Comparison of intestinal mucosal protein
levels of phosphorylated β-catenin according to group. Phosphorylation of β-catenin in group 2 was significantly decreased (P< .05), but
phosphorylation of β-catenin was increased in group 3. (B) β-Catenin expression using immunohistochemistry staining according to
animal group. Compared to group 1, nuclear staining as well as cytoplasmic staining was greatly increased in group 2. However, the
mean percentages of nuclear β-catenin staining were significantly increased in group 2 (P < .05) but significantly decreased in groups 3
and 4 (P < .05). (C) Equal amounts of total protein extracted from small intestine tissues were subjected to Western blot analysis using
the indicated antibodies. (D) TUNEL staining to confirm the apoptosis. Compared to mean TUNEL-positive cells in groups 1 and 2, the
numbers of TUNEL-positive cells were significantly increased in groups 3 and 4 (P < .05). All bars represent the mean and SD of
triplicate values, respectively. (E) Equal amounts of total protein extracted from small intestine tissues were subjected to Western blot
analysis using the indicated antibodies.
Table 2. PPI Suppresses Intestinal Polyposis in the APCMin/+ Mouse.
Group Total Proximal Middle Distal
>2 mm <2 mm >2 mm <2 mm >2 mm <2 mm
Vehicle control (% control) 275 ± 8.07 (100) 2.1 ± 1.2 (100) 1.1 ± 1.8 (100) 5.8 ± 3.8 (100) 8.1 ± 5.7 (100) 6.4 ± 2.6 (100) 10.9 ± 4.9 (100)
Gastrin (% control) 486 ± 12.21* (176) 5.4 ± 2.4 (257) 1.1 ± 1.5* (100) 14.9 ± 7.5 (256) 11.7 ± 5.8* (144) 14.2 ± 9.2 (221) 11.2 ± 6.3† (102)
PPI (% control) 241 ± 8.52‡ (87) 2.1 ± 2.1 (100) 0.6 ± 1.2§ (53) 5.1 ± 3.8 (87) 10.8 ± 6.7§ (79) 6.4 ± 4.7¶ (100) 5.1 ± 4.2¶ (46)
PPI + gastrin (% control) 171 ± 5.08‡ (62) 1.4 ± 1.4 (66) 0.7 ± 1.1‡ (63) 2.9 ± 2.8§,# (50) 4.9 ± 2.4‡ (60) 5.7 ± 5.6§ (89) 3.4 ± 1.6¶ (31)
*P < .01 versus control.
†P < .05 versus control.
‡P < .001 versus gastrin.
§P < .01 versus gastrin.
¶ P < .05 versus gastrin.
#P < .05 versus PPI.
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expression of cyclins and CDK according to group. Similar to the
reports, gastrin administration increased the expression of cyclin D1
and CDK4 (Figure 2C ). Although PPI alone group did not change
cyclin D1 and CDK4, the combination of PPI and gastrin decreased
their expression. In addition, the treatment with combination of
PPI and gastrin downregulated the expressions of cyclin E, CDK2,
and CDK4 in APCMin/+ mice (Figure 2C). Our previous publications
revealed that the anti-tumorigenic action of PPI was through selective
induction of apoptosis in tumors. Therefore, we performed TUNEL
assay as well as Western blot for apoptosis executors. TUNEL staining
result showed significantly increased apoptotic index in either group 3
or group 4 even in polyp neighbor as well as polyp lesion (P < .05;
Figure 2D). Western blot analysis was done to compare the expression
of apoptotic molecules (including caspase-3, caspase-8, and PARP)
and anti-apoptotic molecules (including Bcl-2 and survivin), all of
which were known to be engaged in intestinal polyposis and carcino-
genesis. PPI alone and the combination of PPI and gastrin induced
the expression of cleaved caspase-3 and resulting PARP cleavage,
whereas Bcl-2 expression was decreased (Figure 2E).
Co-Administration of PPI and Gastrin Showed
Anti-Tumorigenic Action through Induction of Apoptosis
and Inhibition of Angiogenic Activities, Mitogen-Activated
Protein Kinase Activation, and Inflammatory Signaling
Because active angiogenesis is also one of the core mechanisms for
the intestinal polyposis of APCMin/+ mice [11], we investigated the
changes of angiogenic activity according to the group through CD31
expression. As seen in Figure 3A, induced expression of CD31 in
APCMin/+ mice as well as increased polyposis in group 2 was all associ-
ated with significant increases than group 1 (P < .05). However, group
3 or group 4 significantly decreased the expression ofCD31 inAPCMin/+
mice (P < .005; Figure 3A). Because these angiogenic activities of
APCMin/+ mice are associated with increased signal transduction activa-
tions, we have compared the active form of mitogen-activated protein
Figure 3. Inflammatory signaling pathway according to animal groups. (A) Gastrin administration in APCMin/+ mice (group 2) significantly
increased the expression of CD31, whereas the expression of CD31 was significantly decreased in groups 3 and 4 (P < .005). (B) The
phosphorylation levels of p38, JNK, and ERK were determined by Western blot analysis. The phosphorylation of MAPKs was significantly
inhibited in groups 3 and 4. (C) Changes in TNF-αmRNA expression and serum protein levels. The treatment with PPI inhibited the levels of
TNF-α induced by gastrin in groups 3 and 4. (D–E) The expression of COX-2 and the level of PGE2 were investigated byWestern blot analysis
and ELISA, respectively. Group 2 showed the induction of COX-2 and PGE2; however, PPI administration decreased the levels of indicated
factors in groups 3 and 4.
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kinases (MAPKs) according to group and found that gastrin activated
the phosphorylation of p38, ERK, and JNK. However, the activation
of MAPKs was all inhibited in either PPI alone or combination of
PPI and gastrin (Figure 3B). Our preliminary cDNA microarray study
demonstrated that gastrin increased the expression of inflammatory
mediators, suggesting that gastrin might increase genes engaged in both
pro-inflammatory and angiogenic actions (data not shown), among
which we have checked the changes of TNF-α and COX-2, genes
known to be principally engaged in intestinal polyposis as well as colon
cancer [12,13]. Though statistically insignificant, the expression of
TNF-α and COX-2 was increased in gastrin-treated group 2, but their
expression was significantly decreased in groups 3 and 4 (Figure 3, C
and D). Similar to COX-2 expression, the level of PGE2, a product of
COX-2, was decreased in both PPI alone and combination of PPI and
gastrin groups but not to a significant level (Figure 3E). The conclu-
sion drawn from the in vivomouse model showed that the combination
of gastrin and PPI exerted significant anti-polyposis effect through
β-catenin inactivation, increased apoptosis, anti-angiogenesis, andMAPK
inactivation relevant to decreased levels of pro-inflammatory mediators.
These novel findings were further documented in the following in vitro
cellular models.
Gastrin exerted trophic effects in a dose-dependent manner, sig-
nificantly in higher dose than 100 nM gastrin in HCT116 colon
cancer cells (P < .05; Figure 4A). PPI significantly decreased cellular
viability in a dose-dependent manner, and PPI showed significantly
higher cytotoxic effect than PPI alone in the presence of 100 nM
gastrin (P < .05; Figure 4B). To investigate the anti-proliferative activ-
ity of PPI alone or the combination of PPI and gastrin, we examined
the cell cycle distribution and apoptosis in HCT116 cells by flow
cytometry. As shown in Figure 4C , quantitation of cells in the G0/G1,
S, and G2/M phases of the cell cycle showed that HCT116 cells ac-
cumulated in the S phase after exposure to gastrin, whereas the cell
Figure 4. Changes of cell viability, cell cycle, and apoptosis in HCT116 cells. Cell viability was observed with MTT assay. (A) Gastrin signif-
icantly increased cell viability in a dose-dependent manner (P < .05). Conversely, PPI decreased cell viability in a dose-dependent manner
(P< .05). (B) The combination of 100, 200, or 400 μM PPI and 100 nM gastrin paradoxically augmented significant decreases in cell viability
(P< .05). All experiments were independently repeated at least three times. *P< .05 versus control; #P< .05 versus PPI; ##P< .01 versus
PPI. (C) Flow cytometric analysis of HCT116 cells synchronized at the G1/S transition by serum starvation and released into the cell cycle
with gastrin, PPI alone, or the combination of PPI and gastrin. The percentage of cells in different phases of the cell cycle was determined
by using theMod-Fit program. (D) HCT116 cells were treated with gastrin, PPI, or the combination for 12 hours and analyzed by flow cytom-
etry for fluorescein isothiocyanate–annexin V and propidium iodide staining to verify the induction of apoptosis. The percentage of cells
in apoptosis was determined by using the Mod-Fit program. (E) HCT116 cells were challenged with gastrin, PPI, or the combination of PPI
and gastrin for 24 hours to investigate the expression of cell cycle markers. The expressions of cyclin D1, cyclin E, and CDK4were assessed
by Western blot analysis. (F) Western blot analysis was performed with antibodies of Bcl-2, cleaved caspase-3 and cleaved caspase-8,
PARP, and survivin, respectively. PPI-treated cells led to apoptosis and cells with the combination of PPI and gastrin promoted more
apoptosis than cells exposed to PPI alone.
Neoplasia Vol. 16, No. 1, 2014 Inhibition of Intestinal Polyposis by PPI Han et al. 79
population in G0/G1 was decreased. The distribution of cell cycle was
restored after treatment with PPI alone or the combination of PPI and
gastrin, suggesting that PPI addition either increased the G0/G1 phase
or decreased the S phase, opening the possibility of cell apoptosis. Flow
cytometry using propidium iodide (PI) and annexin V showed signifi-
cantly decreased apoptotic cell death after treatment with gastrin, but
PPI alone or the combination of PPI and gastrin significantly increased
apoptosis (P < .05; Figure 4D). These findings from flow cytometry
were further validated through Western blot analyses of cyclin D1,
cyclin E, and CDK4 as well as caspase-3, caspase-8, PARP, Bcl-2, and
survivin (Figure 4, E and F). Similar to the data from a previous animal
model (Figure 2C ), gastrin induced the expression of cyclin D1 and
CDK4, but PPI alone and the combination of PPI and gastrin decreased
the expression of cell cycle markers, consistent with the finding of flow
cytometry shown in Figure 4C . Gastrin administration was associated
with either inhibition of PARP cleavage or induction of Bcl-2, but
PPI alone or the combination of PPI and gastrin increased cleavage
of caspase-3, caspases-8, and PARP, whereas the expressions of Bcl-2
and survivin were decreased, indicating that PPI might inhibit the
proliferation of HCT116 cells induced by gastrin through induction
of apoptosis.
Blockade of Gastrin Binding to Its Receptor and
Inactivation of β-Catenin Signaling Might Explain
the Anti-Tumorigenic Action of PPI
To determine whether the anti-proliferative effect of PPI was
through antagonizing the trophic effect of gastrin, we examined the
binding activity of CCKBR-gastrin. As shown in Figure 5A, PPI sig-
nificantly antagonized gastrin-CCKBR binding (P < .05) and the
combination of PPI and gastrin blocked gastrin-CCKBR binding
higher than PPI alone. Because the ultimate trophic effect of gastrin
is executed by Tcf/Lef binding relevant to β-catenin activation [14],
we performed a luciferase reporter assay of Tcf/Lef after the treatment
with gastrin alone, PPI alone, and the combination of PPI and gastrin.
Figure 5. PPI suppresses gastrin-induced trophic effect through blockade of the binding of gastrin to its receptor. (A) To identify binding
activity between CCKBR and gastrin, a sandwich ELISA was performed. PPI alone and the combination of PPI and gastrin significantly
inhibited the binding between CCKBR and gastrin. (B) HCT116 cells were transiently transfected with the pTcf/Lef-Luc reporter vector. After
transfection, the cells were cultured in serum-free medium with gastrin, PPI, or the combination of PPI and gastrin for 12 hours and the
cell lysates were obtained to observe the luciferase activity. The combination of PPI and gastrin significantly decreased the luciferase
reporter activity of Tcf/Lef. (C) Gastrin significantly inactivated GSK3β phosphorylation, but this inactivation was highly recovered with PPI
treatment. (D) HCT116 cells were treated with gastrin, PPI, or the combination of PPI and gastrin for 12 hours and the phosphorylation
of MAPKs was investigated. Gastrin induced the phosphorylation of p38 and ERK and the treatment with PPI downregulated their phos-
phorylations. (E) The changes in angiogenic factors including IL-8, PDGF, HIF-1α, COX-2, and VEGFwere evaluated by reverse transcription–
PCR. Gastrin induced the expression of angiogenic factors; however, PPI and the combination of PPI and gastrin inhibited the expression of
angiogenic factors induced by gastrin.
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As shown in Figure 5B, gastrin significantly increased Tcf/Lef reporter
activity, but the combination of PPI and gastrin markedly inhibited
the Tcf/Lef promoter activity (P < .05). To prove these results by the
combination of PPI and gastrin, we have determined the phosphoryla-
tion of GSK3β, another key regulator engaged in β-catenin activation.
As shown in Figure 5C , gastrin administration abolished the phosphor-
ylation of GSK3β to preserve the proliferative action of β-catenin. How-
ever, PPI alone and the combination of PPI and gastrin restored the
phosphorylation of GSK3β. Because these trophic actions of gastrin
were associated with the activation of MAPKs as seen in Figure 3B,
we examined the levels of p-p38, p-JNK, and p-ERK. As shown in
Figure 5D, treatment with gastrin induced the phosphorylation of
p38 and ERK and these results are consistent with our in vivo findings.
These activations of p38 and ERK were significantly inhibited in the
presence of PPI (Figure 5D). Finally, since tissue analysis fromAPCMin/+
mice showed that gastrin significantly increased CD31 expression
(Figure 3A), we assessed the angiogenic growth factors including
interleukin-8 (IL-8), PDGF, hypoxia-inducible factor-1α (HIF-1α),
COX-2, and VEGF. As shown in Figure 5E , gastrin increased the
expression of all of these angiogenic factors except PDGF, whereas
the expression of these angiogenic factors was all decreased with the
combination of PPI and gastrin. Taken together, we suggest that the
trophic effect of hypergastrinemia relevant to long-term PPI adminis-
tration can be antagonized by paradoxically inhibitory action of PPI on
blocking gastrin binding to CCKBR receptor, thereby facilitating the
inactivation of β-catenin signaling pathway, G0/G1 arrest, and finally
apoptosis in vitro and in vivo intestinal polyposis model.
Discussion
In this study, we found that the combination of PPI and gastrin par-
adoxically inhibited intestinal polyposis even under the mutation
of the apc gene as well as amelioration of gastrin’s trophic effect. PPI
and gastrin synergistically inhibited β-catenin–associated proliferation
signaling as well as gastrin-associated inflammatory mediators. Our
study contains supporting evidence to explain both how long-term
PPI administration plays the preventive role in colitis-associated car-
cinogenesis and the results of a cohort study aimed to reveal the risk
of colon cancer with PPI-associated hypergastrinemia.
Although characterized as a stimulant of gastric acid secretion, the
peptide hormone (gastrin) also exerts growth-promoting effect on
normal and malignant gastrointestinal tissues [15]. Gastrin has also
been shown to induce the growth of colonic gastric carcinoma both
in vivo and in vitro, emphasizing the importance of gastrin as a growth
factor for gastrointestinal neoplasms [1,16]. Several studies have con-
cluded that gastrin is a trophic and mitogenic peptide for normal and
neoplastic gastrointestinal mucosal cells and even cells outside the di-
gestive system [17]. Studies in humans have also shown that higher
levels of circulating gastrin are associated with hypertrophy of the
gastric mucosa and hyperplasia of parietal and enterochromaffin-like
cells [18,19] as well as direct growth-promoting effects of gastrin on
transplanted human colon carcinoma and chemically induced colon
tumors [20,21]. Several reports have demonstrated that activation of
protein kinases in response to gastrin stimulation leads to the induction
of cellular proliferation through a signal transduction pathway that
involves the activation of ERKs [22]. In the present study, treatment
of HCT116 colorectal cancer cells with gastrin (100 nM) led to sig-
nificant proliferation and gastrin treatment induced the progression
of the G1/S phase and the expression of CDK4 and cyclin D1. Progres-
sion from the G1 to the S phase of the cell cycle is regulated by the
periodic expression of cyclin D1 and cyclin E. An increase in the
expression of cyclin D1 is recognized as a critical event in the activation
of the cell cycle machinery of the cell [23], which modulates the activity
of the CDKs, including CDK4, CDK6, and CDK2 [24]. In addition
to these changes, binding of gastrin to the CCKBR induces cell prolif-
eration through promoting cell cycle passage in late G1 and the inhibi-
tion of the binding of gastrin to the CCKBR by YM022 or transient
transfection of siRNA abrogates this effect. The β-catenin/Tcf-4 com-
plex is transported into the nucleus where it acts as a transcription fac-
tor. Because Tcf-4–deficient mice have no proliferating cells in their
intestinal crypts, the β-catenin/Tcf-4 complex is an important regulator
of intestinal proliferation [14]. The identification of gastrin as a func-
tionally relevant upstream target of the β-catenin/Tcf-4 pathway
strengthens the importance of gastrin as a potential target for novel
therapeutic modalities in the treatment of colorectal cancer. We addi-
tionally documented that PPI can be a good therapeutic for colorectal
polyposis as well as cancer because it antagonized the trophic action of
gastrin. We previously reported the overexpression of CCKBR in colo-
rectal cancer HCT116 cells [25], which can explain the reason why the
treatment with gastrin made little change of the binding of gastrin to
the CCKBR compared with the vehicle control in HCT116 cells. To
further investigate the role of PPI in the interaction of gastrin and
CCKBR, we repeated sandwich ELISA in rat small intestinal epithelial
IEC-6 cells. As expected, treatment of IEC-6 cells with gastrin induced
the binding activity of gastrin to its receptor, whereas PPI treatment
inhibited the interaction of gastrin and CCKBR (data not shown),
suggesting the possibility that the structure of PPI might compete with
gastrin to the active site(s) of CCKBR or interfere in the interaction
between gastrin and CCKBR.
The trophic role of gastrin in intestinal polyps is further supported
by polyposis in the APCMin/+ mice model, in which gastrin sig-
nificantly increased intestinal polyposis as well as β-catenin nuclear
translocation. The results from the gastrin-treated APCMin/+ mice
showed a significant increase in polyposis compared with nontreated
APCMin/+ mice, which further strengthened our finding that the
combination of PPI and gastrin paradoxically decreased intestinal
polyposis through inhibiting CCKBR-gastrin binding (Table 2).
Because gastrin is not only important in colon cancer promotion
but also important in the early stages of polyp development, long-
term PPI administration allowed for efficient surveillance of colon
tumorigenesis and a cohort study performed more than 10 years
after PPI use clearly showed that there was no risk of colon cancer
in spite of hypergastrinemia. Clinical studies have indicated that
hypergastrinemia can be associated with an increased risk of colorec-
tal cancer and concerns have been raised about colon cancer risk with
hypergastrinemia caused by PPIs [26]. However, a recent study re-
ported that hypergastrinemia following long-term PPI therapy at a
regular dose is not associated with an increased risk of colorectal can-
cer [4]. In regard to the “colitis-associated carcinogenesis” model, we
recently revealed that repeated colitis increased the expression of
nitric oxide and TNF-α, which ultimately led to tumorigenesis,
but omeprazole treatment efficiently attenuated the generation of
nitric oxide and the expression of TNF-α [9]. However, since a past
study reported that gastric mucosal hypertrophy is frequently asso-
ciated with hypergastrinemia, and the degree of gastritis is related
to the concentration of gastrin [27,28], surely hypersecretion of gas-
trin should be able to modify the epithelial structure by its well-
known ability to promote cellular proliferation and also by regulating
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migration, invasion, and apoptosis [29]. Therefore, we hypothesized
that PPI can provoke hypergastrinemia based on the nature of the
drug and that real biology under the combination of PPI and gastrin
differs from that of gastrin alone, signifying that PPIs exert consid-
erable peculiar biologic actions.
Although PPIs are specifically targeted for blocking hydronium
efflux by inhibiting proton pumps in the apical portion of parietal
cells, PPIs have been shown to exert selective apoptosis-inducing ac-
tions against gastric or colon carcinogenesis, to attenuate Helicobacter
pylori–associated angiogenesis, and to impose significant cytoprotec-
tive actions independent of gastric acid inhibition [30,31]. We have
suggested that PPIs have anti-oxidative and cytoprotective actions
through nuclear factor E2–related factor 2 activation and subsequent
heme oxygenase-1 induction imposes protection from nonsteroidal
anti-inflammatory drug-induced gastroduodenal damages [32].
Gastrin has been known to induce inflammation as evidenced
with increased inflammatory mediators associated with hypergastri-
nemia. We also found that the levels of TNF-α and COX-2 were
increased with gastrin administration in both in vitro colon cells
and in vivo small intestine tissues, explaining the mutual influence
on β-catenin activation and polyposis. As an additional explanation
of the inhibition of polyposis through augmented apoptosis by
PPIs, in spite of the trophic effect of gastrin, the apoptosis-inducing
capacity even in the polyp or tumor prevails with PPIs. Because
maintenance of intracellular or extracellular pH is very important
for cell function and because cancer cells in vivo often exist in an
ischemic microenvironment with a lower extracellular pH than that
of the surrounding normal cells, the acidity in tumors is due to the
increased production of acidic metabolites from rapid and large
amounts of glycolysis and is provoked by the limited ability of the
tumor vasculature to remove these acidic products [33,34]. To over-
come this hypoxic microenvironment and prevent accumulation of
the increased acidic metabolites, the ability to dispose intracellular
protons is critical for cancer cell survival [34,35]. There are some
mechanisms involved in the regulation of pH in tumor tissues.
The main mechanism has reported that a proton (H+) is exported
by the sodium-hydrogen anti-transport using the energy of the
gradient of Na+ [36,37]. In this case, the blocking of H+ efflux by
PPIs might contribute to attenuated polyposis. PPIs successfully sup-
press tumor cell viability by inducing apoptotic cell death. Therefore,
these findings imply that blockage of another kind of proton pump
predominantly expressed in tumor cells could be used as a promising
anti-cancer drug.
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Figure W1. The short tandem repeat profiling results for the HCT116 cell line.
Figure W2. The short tandem repeat profiling results for the HCT116 cell line.
